Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats

Adv Clin Exp Med. 2019 Oct;28(10):1393-1401. doi: 10.17219/acem/104544.

Abstract

Background: Cyclosporine-A (CsA) is widely used for immunosuppressive therapy in renal transplantation. Nephrotoxicity is the main dose-limiting undesirable consequence of CsA. Urotensin II (U-II), a novel peptide with a powerful influence on vascular biology, has been added to the list of potential renal vascular regulators. Upregulation of the urotensin receptors and elevation of plasma U-II levels are thought to possibly play a role in the etiology of renal failure.

Objectives: The present study examines this hypothesis by evaluating renal function and histology with regard to the potential role of U-II and its antagonist, palosuran, in the pathogenesis of CsA-induced nephrotoxicity in rats.

Material and methods: Male Sprague-Dawley rats were treated with CsA (15 mg/kg, for 21 days, intraperitoneally) or CsA + palosuran (300 mg/kg, for 21 days). Renal function was measured and histopathology, U-II immunostaining and protein detection with western blotting of the kidneys were performed.

Results: Cyclosporine-A administration caused a marked decline in creatinine clearance (Ccr). Fractional sodium excretion (FENa) tended to increase in the CsA-treated rats. Plasma U-II levels decreased in the CsA-treated rats. Cyclosporine-A treatment resulted in a marked deterioration in renal histology and an increase in the expression of U-II protein in the kidneys. Palosuran's improvement of renal function manifested as a significant decrease in serum creatinine levels and a significant increase in urine creatinine levels, resulting in a marked increase in Ccr. Palosuran produced a significant normalization of kidney histology and prevented an increase in U-II expression.

Conclusions: Cyclosporine-A-induced renal impairment was accompanied by an increase in U-II expression in kidneys and a contrary decrease in systemic U-II levels. Palosuran improved the condition of rats suffering from renal dysfunction by preventing the decrease in renal U-II expression without affecting the systemic levels of U-II. The protective effect of palosuran in CsA nephrotoxicity is possibly independent of its U-II receptor antagonism.

Keywords: cyclosporine-A; experiment; nephrotoxicity; palosuran; urotensin-II.

MeSH terms

  • Animals
  • Creatinine / blood
  • Creatinine / urine
  • Cyclosporine / adverse effects
  • Cyclosporine / toxicity*
  • Immunosuppressive Agents
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Diseases / chemically induced
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / metabolism
  • Male
  • Models, Animal
  • Quinolines
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Wistar
  • Urea / analogs & derivatives
  • Urotensins / antagonists & inhibitors*

Substances

  • Immunosuppressive Agents
  • Quinolines
  • Urotensins
  • Cyclosporine
  • Urea
  • Creatinine
  • 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea